Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 3,411 matching trials from the live ClinicalTrials.gov search.
Conditions
Fungal Infections
Interventions
Posaconazole
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome
Interventions
Azacitidine, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
7 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 119 more
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate, Indium In 111-DOTA-Basiliximab, Melphalan, Palifermin, Total Lymphoid Irradiation, Total Marrow Irradiation, Yttrium Y 90 Basiliximab
Procedure · Biological · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
AML, MDS, Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Treosulfan, Fludarabine, Total Body Irradiation, Tacrolimus, Mycophenolate Mofetil, Cyclophosphamid, Stem Cell Infusion
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, Fludarabine, Cytoxan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Houston, Texas • Seattle, Washington
Conditions
Leukemia
Interventions
recombinant interferon alfa, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, imatinib mesylate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Duarte, California • Seattle, Washington
Conditions
Bone Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Stereotactic Linear Accelerator
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Multiple Myeloma
Interventions
Bortezomib (Velcade)
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Active, not recruiting Phase 2 Interventional Results available

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions
Procrit
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Biopsy
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Months and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
16
States / cities
Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 13 more
Conditions
Proteus Syndrome
Interventions
MK-7075 (miransertib)
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Myeloma, Plasma-Cell, Lymphoma, Malignant, Myeloproliferative Disorders, Myelodysplastic Syndromes, Waldenstrom's Macroglobulinemia
Interventions
Reduced intensity conditioning with allogeneic transplant
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Leukemia
Interventions
BAY2402234
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
New York, New York • The Bronx, New York • Philadelphia, Pennsylvania + 1 more
Conditions
Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Interventions
EP31670
Drug
Lead sponsor
Epigenetix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma, Progressive Disease, Prostate Carcinoma Metastatic in the Bone, Prostate Carcinoma Metastatic in the Soft Tissue, PSA Progression, Stage IVB Prostate Cancer AJCC v8, Testosterone Less Than 50 ng/dL
Interventions
Recombinant EphB4-HSA Fusion Protein
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois
Conditions
Osteosarcoma
Interventions
Tissue Procurement
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
ENV-101 (taladegib)
Drug
Lead sponsor
Endeavor Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
Conditions
Cancer, Chronic Myelomonocytic Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Malignant Neoplasm of Breast TNM Staging Distant Metastasis (M), Untreated Bone Metastases
Interventions
NaF PET/MRI, NaF PET/CT, FDG PET/CT
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Bony Metastases From Castrate Refractory Prostate Cancer
Interventions
Radium-223 dichloride
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas